PregLem

CompanySwitzerlandFounded 2006

PregLem develops one asset, in phase 3 (PGL4001 in uterine fibroid). Mostly small molecule acting on PGR; based in Switzerland, founded in 2006.

1
Asset
Furthest: Phase 3; 3
Trials: 0
Signals

Pipeline

1

PGL4001
Selective progesterone receptor modulator
Phase 3, Small molecule, PGR, uterine fibroid

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms2
Trials3
Similar companies6

Updated 8 Oct 2026 · 7 sources